MedTrace Logo

Chemotherapy and G-CSF for Mobilization

NCT03442673 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 137

Last updated 2025-03-28

No results posted yet for this study

Summary

This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in myeloma patients.

Conditions

Interventions

DRUG

Vinorelbine

Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells

DRUG

Gemcitabine

Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells

DRUG

G-CSF

Cytokine stimulation with G-CSF for mobilization of autologous stem cells

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Barbara Jeker, MD · Department for Medical Oncology University Hospital/Inselspital 3010 Bern Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2023-03-01
Completion
2024-05-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03442673 on ClinicalTrials.gov